Health

FDA Grants Regular Approval to Rucaparib for Metastatic Castration-Resistant Prostate Cancer

DailyTrendDailyTrend
Dec 22, 2025 - 13:00
 0  1
On December 17, 2025, the Food and Drug Administration (FDA) approved rucaparib (Rubraca, pharmaand GmbH) for adults with a deleterious BRCA mutation (BRCAm) (germline and/or somatic)-associated metastatic castration-resistant prostate cancer...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

RFK Jr. Scales Back the Number of Vaccines Recommended for Children

RFK Jr. Scales Back the Number of Vaccines Recommended ...

DailyTrend Jan 6, 2026  0  1

Infusion Pump Recall: Fresenius Kabi Removes Ivenix Large Volume Pumps

Infusion Pump Recall: Fresenius Kabi Removes Ivenix Lar...

DailyTrend Jan 6, 2026  0  1

Custom Surgical Pack Recall: Alcon Removes Custom Pak Ophthalmic Procedure Packs

Custom Surgical Pack Recall: Alcon Removes Custom Pak O...

DailyTrend Jan 3, 2026  0  1

Vaccines Are Helping Older People More Than We Knew

DailyTrend Jan 4, 2026  0  0

Brenna Henn Wanted to Improve Genetic Medicine. Then Her N.I.H. Grant Was Cut.

Brenna Henn Wanted to Improve Genetic Medicine. Then He...

DailyTrend Jan 2, 2026  0  1

Anesthesia System Correction: GE HealthCare Updates Use Instructions for CareStation Anesthesia Systems

Anesthesia System Correction: GE HealthCare Updates Use...

DailyTrend Dec 30, 2025  0  1